Skip to main content

Table 1 Breakpoints

From: Comparative activity of carbapenem testing (the COMPACT study) in Turkey

Family/Genus (species) FDA CLSI EUCAST
  Doripenem Imipenem/Meropenem Doripenem/Imipenem/Meropenem* Doripenem Imipenem Meropenem
  S I R S I R S I R S I R S I R S I R
Pseudomonas aeruginosa ≤ 2 - - ≤ 4 8 ≥ 16 ≤ 4 8 ≥ 16 ≤ 1 2-4 ≥ 8 ≤ 4 8 ≥ 16 ≤ 2 4-8 ≥ 16
Enterobacteriaceae ≤ 0.5 - - ≤ 4 8 ≥ 16 ≤ 1 2 ≥ 4 ≤ 1 2-4 ≥ 8 ≤ 2 4-8 ≥ 16 ≤ 2 4-8 ≥ 16
Acinetobacter spp. ≤ 1 - - ≤ 4 8 ≥ 16 ≤ 4 8 ≥ 16 ≤ 1 2-4 ≥ 8 ≤ 2 4-8 ≥ 16 ≤ 2 4-8 ≥ 16
  1. FDA US Food and Drug Administration; CLSI Clinical and Laboratory Standards Institute; EUCAST European Committee on Antimicrobial Susceptibility Testing; S susceptible; I intermediate; R resistant
  2. *As of June 2010